Objective: Given changes in U.S. marijuana laws, attitudes, and use patterns, individuals with pain may be an emerging group at risk for nonmedical cannabis use and cannabis use disorder. The authors examined differences in the prevalence of nonmedical cannabis use and cannabis use disorder among U.S. adults with and without pain, as well as whether these differences widened over time.
Methods: Data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, 2001–2002; N=43,093) and NESARC-III (2012–2013; N=36,309) were analyzed using logistic regression. Risk differences of past-year nonmedical cannabis use, frequent (at least three times a week) nonmedical use, and DSM-IV cannabis use disorder were estimated for groups with and without moderate to severe pain, and these risk differences were tested for change over time.
Don't have a subscription to AJPCME? Subscribe online or by phone at 1-800-368-5777.
If you have questions about AJPCME subscriptions, please contact firstname.lastname@example.org.
The participant will identify the role of moderate to severe pain as an emerging risk factor for adult cannabis use disorder.
This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.
Duration: 1 hour
Begin Date: July 1, 2020
End Date: June 30, 2022
In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™). A score of 60% or higher is required to receive credit.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Title: U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001–2002 and 2012–2013
Authors: Deborah S. Hasin, Ph.D., Dvora Shmulewitz, Ph.D., Magdalena Cerdá, Dr.P.H., Katherine M. Keyes, Ph.D., Mark Olfson, M.D., M.P.H., Aaron L. Sarvet, M.P.H., Melanie M. Wall, Ph.D.
Affiliations: New York State Psychiatric Institute, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Psychiatry, Columbia University Medical Center, New York (Hasin, Shmulewitz, Olfson, Wall); Department of Epidemiology (Hasin, Keyes, Olfson) and Department of Biostatistics (Wall), Columbia University Mailman School of Public Health, New York; Department of Population Health, New York University, New York (Cerdá); and Department of Epidemiology, Harvard University School of Public Health, Boston (Sarvet).
Disclosures: Dr. Hasin has received funding from the Campbell Alliance for the validation and use of a measure of opioid addiction among patients with chronic pain. Dr. Keyes has received compensation for consultation on behalf of plaintiff counties in the National Prescription Opioid Litigation. The other authors report no financial relationships with commercial interests.
Discussion of unapproved or investigational use of products*: No.
*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.
Ned H. Kalin, M.D. (Editor-in-Chief, AJP); Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals). Dr. Kalin has served as a consultant to the Board of Scientific Advisors, the Pritzker Neuropsychiatric Disorders Research Consortium, and the Skyland Trail Advisory Board and as Councilor, Society of Biological Psychiatry. Dr. Rodriguez has served as a consultant to Allergan, Blackthorn, Epiodyne, and Rugen. Mr. Roy and Mr. Pogachar report no financial relationships with commercial interests.
Optimal System Configuration:
- Flash Player: Adobe Flash Player 10.1+
- Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
- Operating System: Windows XP+ or Mac OS X 10.4+
- Internet Connection: 1 Mbps or higher
- Screen Resolution: 1024 x 768 pixels.
- Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
- Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit
For assistance: Contact email@example.com for questions about this course | Contact firstname.lastname@example.org for technical assistance